Related Experiment Video

Updated: May 26, 2026

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity
09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Sorafenib: muscle wasting

    Prescrire International
    |January 6, 2012
    PubMed

    Insights

    Sorafenib treatment for advanced cancers can lead to significant muscle loss over time. Patients should be monitored for muscle wasting and its impact on quality of life.

    Area of Science:

    • Oncology
    • Pharmacology
    • Clinical Trials

    Background:

    • Sorafenib is a multi-kinase inhibitor used in treating advanced kidney and liver cancers.
    • Angiogenesis and tumor growth are key pathways targeted by sorafenib.

    Purpose of the Study:

    • To evaluate the impact of sorafenib on skeletal muscle mass in patients with metastatic kidney cancer.
    • To assess the incidence and extent of muscle wasting during sorafenib therapy.

    Main Methods:

    • A placebo-controlled trial involving 80 patients with metastatic kidney cancer.
    • Measurement of skeletal muscle mass at baseline and after 6 months and one year of treatment.

    Main Results:

    • Sorafenib therapy resulted in a statistically significant decrease in skeletal muscle mass.
    • Muscle mass declined by approximately 5% at 6 months and 8% at one year of treatment.

    Conclusions:

    • Sorafenib treatment is associated with significant muscle wasting in patients with metastatic kidney cancer.
    • Clinical assessment for muscle wasting and its consequences, such as loss of autonomy and mobility issues, is crucial when considering sorafenib therapy.

    More Related Videos

    The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia08:55

    The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

    Published on: November 30, 2016

    Related Concept Videos

    Cirrhosis I: Introduction01:23

    Cirrhosis I: Introduction

    Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    Nephrotic Syndrome III : Nursing Management01:24

    Nephrotic Syndrome III : Nursing Management

    Nursing management for nephrotic syndrome adapts as the disease progresses, with strategies evolving to address advancing symptoms and complications.Early-Stage Management In the early stages, nursing interventions for nephrotic syndrome resemble those used in managing acute glomerulonephritis, focusing on symptom monitoring, fluid balance, and managing mild to moderate edema.Vital Signs: Regularly monitor blood pressure, pulse, respiratory rate, and temperature to promptly identify...
    Skeletal Muscle Relaxants: Adverse Effects01:21

    Skeletal Muscle Relaxants: Adverse Effects

    Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
    Unlike...
    Chronic Kidney Disease IV: Nursing Management01:18

    Chronic Kidney Disease IV: Nursing Management

    Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...